Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	5.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or I	P.O. box if mail is not	7 City, town, or post office, state, and ZIP code of contact		
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculat valuation dates ► <u>SE</u>		oasis and the	data that supports the cale	culation, such as the market values of securities and the
-				

Pa	rt II	Organizational Action (continued)		
17	List th	he applicable Internal Revenue Code section(s) and subsection(s) upon whi	ch the tax treatment is based ► <u>S</u>	EE ATTACHMENT
18	Can a	any resulting loss be recognized? ► NONE		
40	Dussil		ha war artable taxvisar N CEE ATTAC	
19	Provid	ide any other information necessary to implement the adjustment, such as t	ne reportable tax year ► SEE ATTAC	HIVIENI
	Un be	nder penalties of perjury, I declare that I have examined this return, including accomplies, it is true corrects and complete. Declaration of preparer (other than officer) is bas	panying schedules and statements, and to ed on all information of which preparer has	the best of my knowledge and any knowledge.
Sig Her	~	gnature Stephen Bardin	1/28/2021 Date ►	
		Stephen Bardin int your name ▶		ce and Operations
Pai		Print/Type properer's name Preparer's signature	Date	⟨ ☐ if PTIN
	iu epare	DOUG BEKKER IN 1 MW		mployed P00439876
	e Onl	·	Firm's	s EIN ► 13-5381590
		Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, N		
Send	d Form	8937 (including accompanying statements) to: Department of the Treasury	, Internal Revenue Service, Ogden, U	T 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 355 shares of its common stock ("New Shares") per 1,000 shares of stock of Adrenas Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Adrenas Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
Name of contact for additional information			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or	P.O. box if mail is no	7 City, town, or post office, state, and ZIP code of contact		
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continu	ued)		
17	List th	e applicable Internal Revenue Code se	ction(s) and subsection(s) upon which the ta	ax treatment is based ▶	SEE ATTACHMENT
-					
-					
18	Can a	ny resulting loss be recognized? ► NC	DNE		
-					
19	Provid	le any other information necessary to in	nplement the adjustment, such as the repor	table tax year ► <u>SEE /</u>	ATTACHMENT
-					
-					
	Und beli	der penalties of perjury, I declare that I have lef, it is true. correct; and complete. Declarat	examined this return, including accompanying seion of preparer (other than officer) is based on all in	chedules and statements, nformation of which prepa	and to the best of my knowledge and arer has any knowledge.
Sig					
Her	<u>م</u>	nature Stephen Bardin		1/28/2 Date ►	021
	Olgi	Stephen Bardin		VP, Fi	nance and Operations
	Prir	nt your name ►	Propagaria aignatura	Title ►	DT0:
Pai	id	Print/Type preparer's name	Preparer's signature	Date 12/14/2020	Check if PTIN
	pare		in I kun	12/14/2020	self-employed P00439876
Us	e Only	Firm's name BDO USA, LLP	NIM CTE 000 CDAND DATES AN ATTE		Firm's EIN ▶ 13-5381590
Sono	d Form (E NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
OCIT	4 I UIIII (see the statement accompanying statement	nts) to: Department of the Treasury, Internal	r rieveriue Service, Ogo	JOH, OT 04201-0004

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 31 shares of its common stock ("New Shares") per 1,000 shares of stock of ASPA Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from ASPA Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are \$361, \$368(a)(1)(B), \$354, and \$358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
Name of contact for additional information			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or	P.O. box if mail is no	7 City, town, or post office, state, and ZIP code of contact		
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)		
17	List the	e applicable Internal Revenue Code section(s) and subsection(s)	upon which the tax treatment is based ▶	SEE ATTACHMENT
18	Can ar	ny resulting loss be recognized? ► NONE		
10	Drovid	e any other information necessary to implement the adjustment,	auch as the reportable tay year > CEE ATT	ACHMENT
19	FIOVIG	e any other information necessary to implement the adjustment,	such as the reportable tax year > SEE ATT	ACHIVIENT
	Line	ler penalties of perjury, I declare that I have examined this return, includ	ing accompanying schodules and statements, and	to the best of my knowledge and
	beli	ef, it is true_corpectsand complete. Declaration of preparer (other than off	ing accompanying scriedules and statements, and icer) is based on all information of which preparer	has any knowledge.
Sig Her		Stylun Bardin	1/28/202	1
	Olgi	Stephen Bardin		nce and Operations
_	•	t your name ► Print/Type preparer's name Preparer's signature	Title ► Date	PTIN
Pai		Lauren I M.	12/14/2020 Ch	leck
	eparer e Only	V		m's EIN ► 13-5381590
<u></u>		Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND F		one no. 616-774-7000
Send	d Form 8	937 (including accompanying statements) to: Department of the	Treasury, Internal Revenue Service, Ogden	UT 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 328 shares of its common stock ("New Shares") per 1,000 shares of stock of Calcilytix Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Calcilytix Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
Name of contact for additional information			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or	P.O. box if mail is no	7 City, town, or post office, state, and ZIP code of contact		
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)		
17	List th	e applicable Internal Revenue Code section(s) and subsection(s	s) upon which the tax treatment is based >	SEE ATTACHMENT
-				
-				
18	Can a	ny resulting loss be recognized? ► NONE		
-				
-				
19	Provid	le any other information necessary to implement the adjustment	t, such as the reportable tax year ▶ SEE A	TTACHMENT
-				
-				
	Unc	der penalties of perjury, I declare that I have examined this return, inclu	ding accompanying schedules and statements	and to the best of my knowledge and
	beli	ef, it is true, correct, and complete. Declaration of preparer (other than o	fficer) is based on all information of which prepare	rer has any knowledge.
Sig			1/28/20	
Hei		nature Stephen Bardin	Date ▶	
		Stephen Bardin	VP, Fin	ance and Operations
_	•	nt your name ► Print/Type preparer's name Preparer's signature	Title ► Date	Obasti D # PTIN
Pai			12/14/2020	Check if self-employed P00439876
	pare			1 00 100070
Us	e Only	Firm's name ► BDO USA, LLP Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND	RAPIDS MI 49503	Firm's EIN ► 13-5381590 Phone no. 616-774-7000
Send	d Form 8	3937 (including accompanying statements) to: Department of th		

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 40 shares of its common stock ("New Shares") per 1,000 shares of stock of CoA Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from CoA Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
Name of contact for additional information			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or	P.O. box if mail is no	7 City, town, or post office, state, and ZIP code of contact		
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt III	Organizational Action (continued)			
17	List the	e applicable Internal Revenue Code section(s) and s	ubsection(s) upon which the tax t	treatment is based ▶	SEE ATTACHMENT
18	Can ar	ny resulting loss be recognized? ► NONE			
10	Drovid		adjustment auch as the reservator	ole toy year > CEE	
19	FIOVIO	e any other information necessary to implement the	adjustifierit, such as the reportat	Die tax year > SEE F	ATTACHWENT
	Lind	er penalties of perjury, I declare that I have examined this	raturn including accompanying solv	adulas and statements	and to the best of my knowledge and
	belie	er penalties of penalty, i declare that i have examined this ef, it is true_ <u>corect</u> signers applete. Declaration of preparer	(other than officer) is based on all info	ormation of which preparation	arer has any knowledge.
Sig	n	Stadun Bardin		1/28/2	021
Hei		oature Stephen Bardin		Date ►	
	Prin	Stephen Bardin tyourname▶		VP, Fi	nance and Operations
Pai	•	Print/Type preparer's name Prepare	r's signature	Date	Check if PTIN
	ıu eparer	Laura Berrysen	1 Km	12/14/2020	self-employed P00439876
	e Only	Firm's name ► BDO USA, LLP	<u> </u>		Firm's EIN ► 13-5381590
		Firm's address ► 200 OTTAWA AVE NW STE 30			Phone no. 616-774-7000
Send	d Form 8	937 (including accompanying statements) to: Depa	rtment of the Treasury, Internal R	evenue Service, Ogo	den, UT 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 166 shares of its common stock ("New Shares") per 1,000 shares of stock of Ferro Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Ferro Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
Name of contact for additional information			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or	P.O. box if mail is no	7 City, town, or post office, state, and ZIP code of contact		
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)		
17	List	st the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax tr	eatment is based ▶	SEE ATTACHMENT
-				
-				
18	Car	an any resulting loss be recognized? ► NONE		
19	Pro	ovide any other information necessary to implement the adjustment, such as the reportable	le tax year ▶ <u>SEE</u> A	ATTACHMENT
-				
		Under penalties of perjury, I declare that I have examined this return, including accompanying schedulers	dules and statements	and to the best of my knowledge an
	l i	belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all infor	mation of which prepa	arer has any knowledge.
Sig			1/28/2	
Her	_	Signature Stephen Bardin	Date ►	.022
		Stephen Bardin Print your name ►		nance and Operations
D~:		Print/Type preparer's name Preparer's signature	Date	Charle D if PTIN
Pai		5 / W A A	12/14/2020	Check if P00439876
	par	only Firm's name ► BDO USA, LLP	-	Firm's EIN ► 13-5381590
<u>US</u>	. UI	Firm's address > 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d For	rm 8937 (including accompanying statements) to: Department of the Treasury, Internal Re	venue Service, Ogo	

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 255 shares of its common stock ("New Shares") per 1,000 shares of stock of Fortify Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Fortify Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
STEPHEN BARDIN 650-391-9740 6 Number and street (or P.O. box if mail is not delivered to street address) of contact				7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)			
17	List th	e applicable Internal Revenue Code section(s	s) and subsection(s) upon which the tax tr	eatment is based ▶	SEE ATTACHMENT
18	Can a	ny resulting loss be recognized? ► NONE			
19	Provio	e any other information necessary to implem	ant the adjustment, such as the reportable	o tay your N SEE /	ATTACHMENT
19	FIOVIC	e arry other information necessary to implem	ent the adjustment, such as the reportable	e lax year > SEE F	TIACHWENT
	Und	ler penalties of perjury, I declare that I have exami	ned this return, including accompanying sched	dules and statements,	and to the best of my knowledge and
C:~		ef, it is true, correct, and complete. Declaration of p	reparer (other than officer) is based on all infor		
Sig Her	~	Stephen Bardin		1/28/20	021
1101	Sig	007DCCFA87FF4A3		Date ▶	
	Drin	Stephen Bardin tyourname►		VP, Fī	inance and Operations
		1	Preparer's signature	Date	Check I if PTIN
Pai		DOLLO DELL'ILED	in I ku	12/14/2020	Check if 11111 11111 1111 1111 1111 11111 1111 1111 1111 11
	epare		· * · · · ·	<u>'</u>	Firm's EIN ► 13-5381590
	<u> </u>	Firm's address ► 200 OTTAWA AVE NW	STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d Form 8	3937 (including accompanying statements) to	: Department of the Treasury, Internal Re	venue Service, Ogo	den, UT 84201-0054

Fortify Therapeutics, Inc.

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 84 shares of its common stock ("New Shares") per 1,000 shares of stock of Molecular Skin Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Molecular Skin Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
STEPHEN BARDIN 650-391-9740 6 Number and street (or P.O. box if mail is not delivered to street address) of contact				7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)		
17	List t	the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax	treatment is based ▶	SEE ATTACHMENT
18	Can a	any resulting loss be recognized? ► YES		
19	Provi	ride any other information necessary to implement the adjustment, such as the reporta	ıble tax vear ▶ SEF /	ATTACHMENT
	11011	and any other mornation recoccity to important the adjustment, such as the reporta	SEL P	TIACHWENT
	Ur	nder penalties of perjury, I declare that I have examined this return, including accompanying sch elief, it is true, cor rect នាក្រុស ្នែល្អាplete. Declaration of preparer (other than officer) is based on all inf	nedules and statements,	and to the best of my knowledge and
C:		(
Sig Her		ignature Stephen Bardin	1/28/20	021
1101		Stephen Bardin		ance and Operations
		rint your name ► Print/Type preparer's name Preparer's signature	Title ► Date	Observation of PTIN
Pai			12/14/2020	Check III
	pare	er Soos services 1740 L	1	self-employed P00439876 Firm's EIN ► 13-5381590
US	e Onl	Firm's address > 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d Form	n 8937 (including accompanying statements) to: Department of the Treasury, Internal F	Revenue Service, Ogo	

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 226 shares of its common stock ("New Shares") per 1,000 shares of stock of Navire Pharma, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to the aggregate fair market value of New Shares received as of the date of action.

Page 1, Part II, Line 16

A U.S. person will have change in basis as a result of this exchange. The basis in New Shares will be equal to the aggregate fair market value of the New Shares received on the date of action.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are \$1001, \$1011, and \$1012

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
STEPHEN BARDIN 650-391-9740 6 Number and street (or P.O. box if mail is not delivered to street address) of contact				7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt III	Organizational Action (continued)		
17	List the	e applicable Internal Revenue Code section(s) and subsection(s) upon whic	ch the tax treatment is based ▶	SEE ATTACHMENT
18	Can ar	ny resulting loss be recognized? ► YES		
	Ourrai	19 1000 titing 1000 be 1000gm20d . P		
19	Provid	le any other information necessary to implement the adjustment, such as the	ie reportable tax year ► <u>SEE A</u>	TTACHMENT
	Und	der penalties of perjury, I declare that I have examined this return, including accomper, it is true. corpects and complete. Declaration of preparer (other than officer) is base	anying schedules and statements,	and to the best of my knowledge and
Sig			1/28/20	
Her		nature Stephen Bardin	1/ 28/ 20 Date ▶	21
	Oigi	Stephen Bardin	VP, Fir	ance and Operations
<u> </u>		nt your name ► Print/Type preparer's name Preparer's signature	Title ► Date	Chack D if PTIN
Pai	d eparer	boundarius IV. A./	12/14/2020	Check if '''' self-employed P00439876
	e Only	·	'	Firm's EIN ▶ 13-5381590
		Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, M		Phone no. 616-774-7000
Send	d Form 8	3937 (including accompanying statements) to: Department of the Treasury,	Internal Revenue Service, Ogd	en, UT 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 315 shares of its common stock ("New Shares") per 1,000 shares of stock of Orfan Biotech Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to the aggregate fair market value of New Shares received as of the date of action.

Page 1, Part II, Line 16

A U.S. person will have change in basis as a result of this exchange. The basis in New Shares will be equal to the aggregate fair market value of the New Shares received on the date of action.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are \$1001, \$1011, and \$1012

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
STEPHEN BARDIN 650-391-9740 6 Number and street (or P.O. box if mail is not delivered to street address) of contact				7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)		
17	List t	the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax	treatment is based ▶	SEE ATTACHMENT
-				
18	Can	any resulting loss be recognized? ► NONE		
-				
19	Prov	ride any other information necessary to implement the adjustment, such as the reporta	able tax year ► <u>SEE A</u>	ATTACHMENT
-				
	U	Inder penalties of perjury, I declare that I have examined this return, including accompanying sch	nedules and statements,	and to the best of my knowledge and
		elief, it is true, correct usign compelete. Declaration of preparer (other than officer) is based on all inf	ormation of which prepa	arer has any knowledge.
Sig		Stephen Bardin	1/28/2	021
Hei	′e _{Si}	ignature ►	Date ►	
	Pi	Stephen Bardin rint your name ▶	- - VP, Fir Title▶	nance and Operations
Do:		Print/Type preparer's name Preparer's signature	Date	Check if PTIN
Pai		DOUG DEWYER	12/14/2020	self-employed P00439876
	epare e On	er The last term The last		Firm's EIN ► 13-5381590
_	- UII	Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d Form	n 8937 (including accompanying statements) to: Department of the Treasury, Internal F	Revenue Service, Ogo	

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 133 shares of its common stock ("New Shares") per 1,000 shares of stock of Origin Biosciences, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Origin Biosciences, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
STEPHEN BARDIN 650-391-9740 6 Number and street (or P.O. box if mail is not delivered to street address) of contact				7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)		
17	List	ist the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax t	reatment is based ▶	SEE ATTACHMENT
-				
-				
18	Car	an any resulting loss be recognized? ► YES		
-				
19	Pro	rovide any other information necessary to implement the adjustment, such as the reportab	ole tax year ▶ <u>SEE A</u>	ATTACHMENT
-		Under penalties of perjury, I declare that I have examined this return, including accompanying sche	dules and statements,	and to the best of my knowledge and
		belief, it is true, correct and complete. Declaration of preparer (other than officer) is based on all info	rmation of which prepa	arer has any knowledge.
Sig		Signature Stephen Bardin	1/28/	2021
Her	е	Signature ►	Date ►	
		Stephen Bardin Print your name ▶	VP, F	inance and Operations
Pai	id	Print/Type preparer's name Preparer's signature	Date	Check if PTIN
		DOUG BEKKER DOUG BEKKER	12/14/2020	self-employed P00439876
		Only Firm's name ► BDO USA, LLP		Firm's EIN ► 13-5381590
		Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d For	orm 8937 (including accompanying statements) to: Department of the Treasury, Internal Re	evenue Service, Ogo	den, UT 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 75 shares of its common stock ("New Shares") per 1,000 shares of stock of Phoenix Tissue Repair, Inc ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to the aggregate fair market value of New Shares received as of the date of action.

Page 1, Part II, Line 16

A U.S. person will have change in basis as a result of this exchange. The basis in New Shares will be equal to the aggregate fair market value of the New Shares received on the date of action.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are \$1001, \$1011, and \$1012

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	C.			84-1850815
3 Name of contact for additional information 4 Telephone No. of contact			5 Email address of contact	
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
STEPHEN BARDIN 650-391-9740 6 Number and street (or P.O. box if mail is not delivered to street address) of contact				7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
16 Describe the calculate valuation dates ► <u>SE</u>	_	basis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt III	Organizational Action (continued)		
17	List t	he applicable Internal Revenue Code section(s) and subsection(s) upon which the tax to	reatment is based	SEE ATTACHMENT
-				
18	Can a	any resulting loss be recognized? ► NONE		
-				
19	Provi	de any other information necessary to implement the adjustment, such as the reportab	le tax year ► <u>SEE <i>F</i></u>	ATTACHMENT
-				
-				
-				
	Ur	nder penalties of perjury, I declare that I have examined this return, including accompanying sche	dules and statements,	and to the best of my knowledge and
	I	elief, it is true, correct and complete. Declaration of preparer (other than officer) is based on all infor	mation of which prepa	arer has any knowledge.
Sig Her		Stephen Bardin	1/28/20)21
He	Sig	gnature ►	Date ►	
	Pr	Stephen Bardin intyourname▶	Title ►	nance and Operations
Pai	id	Print/Type preparer's name Preparer's signature	Date	Check if PTIN
	pare	DOUG BEKKER IN 1 MW	12/14/2020	self-employed P00439876
	e Onl	· · · · · · · · · · · · · · · · · · ·		Firm's EIN ► 13-5381590
		Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d Form	8937 (including accompanying statements) to: Department of the Treasury, Internal Re	venue Service, Ogo	den, UT 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 109 shares of its common stock ("New Shares") per 1,000 shares of stock of QED Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from QED Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	S.			84-1850815
3 Name of contact for ad		4 Telephoi	ne No. of contact	5 Email address of contact
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or I	P.O. box if mail is not	delivered to		7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
Describe the calculativaluation dates ► <u>SE</u>	_	oasis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt II	Organizational Action (continued)			
17	List the	e applicable Internal Revenue Code section(s) and	d subsection(s) upon which the tax	treatment is based ▶	SEE ATTACHMENT
18	Can ar	ny resulting loss be recognized? ► NONE			
19	Provid	e any other information necessary to implement t	the adjustment such as the reports	hle tay year 🕨 SEE /	\TTACHMENT
10	TTOVIG	sarry other information necessary to implement t	the adjustificiti, such as the reporta	ibic tax year > <u>SEL P</u>	TIACHWENT
	Und	er penalties of perjury, I declare that I have examined to	this return, including accompanying sch	edules and statements,	and to the best of my knowledge and
C:~		ef, it is true <u>. correct sind a sym</u> plete. Declaration of prepa	irer (other than officer) is based on all little		
Sig Her		Stephen Bardin		1/28/20	021
1101	Sign	nature►		_ Date▶ VP, Fir	nance and Operations
	Prin	t your name ►	aror's signature	Title ► Date	DTIM
Pai		BOLLO BELLIKED	arer's signature	12/14/2020	Check if PTIN
	parer		V 1 ·2000	12/14/2020	self-employed P00439876
Us	e Only	Firm's name ► BDO USA, LLP Firm's address ► 200 OTTAWA AVE NW STE	300 GRAND RAPIDS MI 40503		Firm's EIN ► 13-5381590 Phone no. 616-774-7000
Send	d Form 8	937 (including accompanying statements) to: De		Revenue Service, Ogo	

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 75 shares of its common stock ("New Shares") per 1,000 shares of stock of Retinagenix Therapeutics, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Retinagenix Therapeutics, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	S.			84-1850815
3 Name of contact for ad		4 Telephoi	ne No. of contact	5 Email address of contact
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or I	P.O. box if mail is not	delivered to		7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
Describe the calculativaluation dates ► <u>SE</u>	_	oasis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt III	Organizational Action (continued)		
17	List t	the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax	treatment is based ▶	SEE ATTACHMENT
-				
-				
18	Can	any resulting loss be recognized? ► NONE		
-				
-				
19	Provi	ide any other information necessary to implement the adjustment, such as the reporta	ole tax year ► SEE A	ATTACHMENT
	116	nder penalties of perjury, I declare that I have examined this return, including accompanying sch	adulas and statements	and to the best of my knowledge and
	be	elief, it is true, correct and compelete. Declaration of preparer (other than officer) is based on all info	edules and statements, ermation of which prepa	arer has any knowledge.
Sig			1/28/2	
Her		ignature Stephen Bardin	Date ▶	
	5		·	inance and onersticus
	 Dr	Stephen Bardin rint your name ▶	VP, F1	nance and Operations
D~:		Drint/Time arrangement and a Property Company	Date	Chook T if PTIN
Pai		DOUG DEWYER	12/14/2020	Check if ' '''' self-employed P00439876
	pare	V	1	Firm's EIN ► 13-5381590
US	e On	Firm's address ► 200 OTTAWA AVE NW STE 300, GRAND RAPIDS, MI 49503		Phone no. 616-774-7000
Send	d Form	n 8937 (including accompanying statements) to: Department of the Treasury, Internal R	evenue Service, Ogo	

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 324 shares of its common stock ("New Shares") per 1,000 shares of stock of Theras, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Theras, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions

Internal Revenue Service			See separate instruction	15.
Part I Reporting	Issuer			
1 Issuer's name				2 Issuer's employer identification number (EIN)
BRIDGEBIO PHARMA, INC	S.			84-1850815
3 Name of contact for ad		4 Telephoi	ne No. of contact	5 Email address of contact
STEPHEN BARDIN			650-391-9740	stephen.bardin@bridgebio.com
6 Number and street (or I	P.O. box if mail is not	delivered to		7 City, town, or post office, state, and ZIP code of contact
421 KIPLING ST.				PALO ALTO, CA 94301
8 Date of action		9 Clas	sification and description	
MAY 19, 2020		СОММС	N STOCK EXCHANGE	
10 CUSIP number	11 Serial number		12 Ticker symbol	13 Account number(s)
28249H104	N/A		BBIO	N/A
		ch additiona		See back of form for additional questions.
the action ► <u>SEE A</u>	TTACHMENT			
15 Describe the quantita share or as a percent				curity in the hands of a U.S. taxpayer as an adjustment per
Describe the calculativaluation dates ► <u>SE</u>	_	oasis and the	data that supports the cal	culation, such as the market values of securities and the

Pa	rt III	Organizational Action (continued)			
17	List the	e applicable Internal Revenue Code section(s) and su	ubsection(s) upon which the tax t	reatment is based ▶	SEE ATTACHMENT
18	Can ar	y resulting loss be recognized? ► NONE			
		-			
19	Provid	e any other information necessary to implement the	adjustment, such as the reportab	lo tay yoar > SEE /	ATTACUMENT
19	FIOVIU	e any other information necessary to implement the	adjustifierit, such as the reportab	ie tax year > SEE F	ATTACHIVENT
	Und belie	er penalties of perjury, I declare that I have examined this of, it is true, correct and complete. Declaration of preparer (return, including accompanying sche other than officer) is based on all info	dules and statements, mation of which prepa	and to the best of my knowledge and arer has any knowledge.
Sig Her		ature Stephen Bardin		1/28/2 Date▶	021
		Stephen Bardin			nance and Operations
Pai		Print/Type preparer's name Preparer	's signature	Date	Check if PTIN
	u eparer	DOUG BEKKER /W	1 km	12/14/2020	self-employed P00439876
	e Only	Firm's name ► BDO USA, LLP	t		Firm's EIN ▶ 13-5381590
		Firm's address ► 200 OTTAWA AVE NW STE 300			Phone no. 616-774-7000
Send	d Form 8	937 (including accompanying statements) to: Depar	tment of the Treasury, Internal Re	evenue Service, Ogo	den, UT 84201-0054

Page 1, Part II, Line 14

On May 19, 2020, BridgeBio Pharma, Inc. exchanged 211 shares of its common stock ("New Shares") per 1,000 shares of stock of Venthera, Inc. ("Existing Shares").

Page 1, Part II, Line 15

A U.S. person's basis in the New Shares received from BridgeBio Pharma, Inc. will be equal to their basis in the Existing Shares received from Venthera, Inc.

Page 1, Part II, Line 16

A U.S. person will have no change in basis as a result of this exchange. The basis in the Existing Shares is transferred to the New Shares received.

Page 2, Part II, Line 17

Applicable Internal Revenue Code sections and subsections are §361, §368(a)(1)(B), §354, and §358.

Page 2, Part II, Line 19